US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jade Biosciences

7.71

+0.52007.23%

Post-market: 8.120.4100+5.32%19:25 EDT

Volume:674.02K

Turnover:5.11M

Market Cap:248.54M

PE:-4.55

High:8.45

Open:8.08

Low:7.27

Close:7.19

Loading ...

Overview Company News Filings

Jade Biosciences presents JADE101 preclinical data at ERA Congress

Jade Biosciences Inc - Jade101 Shows Sustained Iga Reductions and Potential for 8-Week Dosing

THOMSON REUTERS

Jade Biosciences Inc - First-in-Human Trial of Jade101 Expected to Begin Second Half 2025

THOMSON REUTERS

Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data

Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress

CEO’s Bold Move: Major Stock Purchase at Jade Biosciences

CEO Tom Frohlich Acquires Common Shares of Jade Biosciences Inc

Jade Biosciences Price Target Maintained With a $17.00/Share by Wedbush

Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

Jade Biosciences Inc. Completes Merger with Aerovate Therapeutics, Inc. to Advance Autoimmune Disease Therapies

US Equity Futures Higher as Trump Considers 80% China Tariffs

MT Newswires Live

Jade Biosciences Initiated at Outperform by Wedbush

Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target

MT Newswires Live

Jade Biosciences Inc : Stifel Initiates Coverage With Buy Rating; Target Price $19

THOMSON REUTERS

Aerovate Therapeutics Completes Merger with Jade Biosciences

Aerovate Therapeutics Inc trading halted, news pending

Press Release: Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

BRIEF-Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals

Aerovate Therapeutics Inc - Stockholders Approve Merger With Jade Biosciences

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/JBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"JBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","market":"US","secType":"STK","nameCN":"Jade Biosciences","latestPrice":7.71,"timestamp":1749499200000,"preClose":7.19,"halted":0,"volume":674022,"hourTrading":{"tag":"盘后","latestPrice":8.12,"preClose":7.71,"latestTime":"19:25 EDT","volume":7614,"amount":60877.9074,"timestamp":1749511531701},"delay":0,"floatShares":30421663,"shares":32235900,"eps":-1.69532,"marketStatus":"Not Yet Opened","change":0.52,"latestTime":"06-09 16:00:00 EDT","open":8.08,"high":8.4531,"low":7.265,"amount":5106148.698102,"amplitude":0.165243,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.69532,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749542400000},"marketStatusCode":0,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":7.19,"preHourTrading":{"tag":"盘前","latestPrice":8,"preClose":7.19,"latestTime":"09:29 EDT","volume":2740,"amount":22691.504539999998,"timestamp":1749475770016},"postHourTrading":{"tag":"盘后","latestPrice":8.12,"preClose":7.71,"latestTime":"19:25 EDT","volume":7614,"amount":60877.9074,"timestamp":1749511531701},"volumeRatio":2.080378,"impliedVol":1.58,"impliedVolPercentile":0.0714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","floatShares":30421663,"roa":"--","roe":"--","lyrEps":-2.436062,"volumeRatio":2.080378,"shares":32235900,"dividePrice":0,"high":8.4531,"amplitude":0.165243,"preClose":7.19,"low":7.265,"week52Low":6.71,"pbRate":"-5.31","week52High":884.975,"institutionHeld":0,"latestPrice":7.71,"eps":-1.69532,"divideRate":0,"volume":674022,"delay":0,"ttmEps":-1.69532,"open":8.08,"prevYearClose":92.75,"prevWeekClose":7.19,"prevMonthClose":7.25,"prevQuarterClose":87.85,"fiveDayClose":7.2,"twentyDayClose":8.65,"sixtyDayClose":86.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"JBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542389101","title":"Jade Biosciences presents JADE101 preclinical data at ERA Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2542389101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542389101?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:10","pubTimestamp":1749467433,"startTime":"0","endTime":"0","summary":"Jade Biosciences (JBIO) announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand monoclonal antibody,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jade-biosciences-presents-jade101-preclinical-data-at-era-congress-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jade-biosciences-presents-jade101-preclinical-data-at-era-congress-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","JBIO"],"gpt_icon":0},{"id":"2542386735","title":"Jade Biosciences Inc - Jade101 Shows Sustained Iga Reductions and Potential for 8-Week Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2542386735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542386735?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:04","pubTimestamp":1749467096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nFWN3SA01C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","JBIO","BK4139"],"gpt_icon":0},{"id":"2542386731","title":"Jade Biosciences Inc - First-in-Human Trial of Jade101 Expected to Begin Second Half 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542386731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542386731?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:04","pubTimestamp":1749467096,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nFWN3SA01C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2542408386","title":"Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2542408386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542408386?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:00","pubTimestamp":1749466838,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy . Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLWc4xq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","JBIO","BK4539","BK4112","BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2540762701","title":"Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762701?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:00","pubTimestamp":1748862040,"startTime":"0","endTime":"0","summary":"Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy , will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL25JFkg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","JBIO","BK4588","IE00B3QW5Z07.USD","BK4139","BK4539","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2536047650","title":"CEO’s Bold Move: Major Stock Purchase at Jade Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2536047650","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536047650?lang=en_us&edition=fundamental","pubTime":"2025-05-20 10:12","pubTimestamp":1747707134,"startTime":"0","endTime":"0","summary":"New insider activity at Jade Biosciences ( ($JBIO) ) has taken place on May 20, 2025. Chief Executive Officer Tom Frohlich has made a significant i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","JBIO","BK4139"],"gpt_icon":0},{"id":"2536460630","title":"CEO Tom Frohlich Acquires Common Shares of Jade Biosciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536460630","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536460630?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:54","pubTimestamp":1747688085,"startTime":"0","endTime":"0","summary":"Tom Frohlich, the Chief Executive Officer and Director of Jade Biosciences Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL5hg8VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2535827408","title":"Jade Biosciences Price Target Maintained With a $17.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535827408?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:08","pubTimestamp":1747321680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:08 ET (15:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2535488146","title":"Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2535488146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535488146?lang=en_us&edition=fundamental","pubTime":"2025-05-15 06:45","pubTimestamp":1747262711,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on JBIO stock, giving a Buy rating on May 7. Tyler Van Buren has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-future-for-jade-biosciences-buy-rating-backed-by-innovative-jade101-and-experienced-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-future-for-jade-biosciences-buy-rating-backed-by-innovative-jade101-and-experienced-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JBIO"],"gpt_icon":0},{"id":"2535000700","title":"Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000700","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000700?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:42","pubTimestamp":1747255376,"startTime":"0","endTime":"0","summary":"Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421947/jade-biosciences-q1-eps-12-10-misses-1-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2535600725","title":"Jade Biosciences Inc. Completes Merger with Aerovate Therapeutics, Inc. to Advance Autoimmune Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2535600725","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535600725?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:20","pubTimestamp":1747254048,"startTime":"0","endTime":"0","summary":"Jade Biosciences, Inc. has announced the completion of its merger with Aerovate, resulting in the formation of a new entity named the Combined Company. This merger involved the integration of Jade Biosciences, LLC into Jade Biosciences, Inc., and the newly formed entity will continue under the name Jade Biosciences, Inc. Led by Jade's pre-merger management team, the Combined Company will focus on developing innovative biologic therapies for autoimmune diseases. The merger reflects Jade Biosciences' strategy to enhance its development capabilities and expand its portfolio in the biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL5gSsBv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JBIO"],"gpt_icon":0},{"id":"2534866054","title":"US Equity Futures Higher as Trump Considers 80% China Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2534866054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534866054?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:14","pubTimestamp":1746792858,"startTime":"0","endTime":"0","summary":"US stock futures were higher in premarket activity Friday after US President Donald Trump posted on Truth Social that an \"80% tariff on China seems right!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","EQR","TQQQ","BBGI","MNQmain","USJW.SI","BK4139","DJX","NVIW.SI","QID","BK4585","USAW.SI","NQmain","DXD",".IXIC","BK4215","BK4588","BK4190","CRVS","IOVA",".SPX","UDOW","SQQQ","DDM",".DJI","VEEE","TSYW.SI","BK4006","QLD","JBIO","BK4125","DOG","PSQ","ZKIN","BK4539","SDOW","MYMmain"],"gpt_icon":1},{"id":"2533953012","title":"Jade Biosciences Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2533953012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533953012?lang=en_us&edition=fundamental","pubTime":"2025-05-07 23:57","pubTimestamp":1746633420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2025 11:57 ET (15:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2533837005","title":"Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2533837005","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533837005?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:38","pubTimestamp":1746445130,"startTime":"0","endTime":"0","summary":"Jade Biosciences, Inc. (JBIO) has an average rating of overweight and mean price target of $62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SF","JBIO"],"gpt_icon":0},{"id":"2533830701","title":"Jade Biosciences Inc : Stifel Initiates Coverage With Buy Rating; Target Price $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2533830701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533830701?lang=en_us&edition=fundamental","pubTime":"2025-05-05 18:46","pubTimestamp":1746441977,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD1MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JBIO","BK4139"],"gpt_icon":0},{"id":"2532835187","title":"Aerovate Therapeutics Completes Merger with Jade Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2532835187","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532835187?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:52","pubTimestamp":1746132723,"startTime":"0","endTime":"0","summary":"Aerovate Therapeutics ( ($AVTE) ) has provided an update. On April 28, 2025, Jade Biosciences, Inc. completed its merger with Aerovate Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aerovate-therapeutics-completes-merger-with-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aerovate-therapeutics-completes-merger-with-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JBIO","BK4007","LENZ"],"gpt_icon":0},{"id":"2531291572","title":"Aerovate Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291572?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:50","pubTimestamp":1745884207,"startTime":"0","endTime":"0","summary":"19:50 EDT Aerovate Therapeutics (AVTE) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aerovate-therapeutics-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aerovate-therapeutics-inc-trading-halted-news-pending-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JBIO","LENZ","BK4007","AVTE","BK4539"],"gpt_icon":0},{"id":"2530840242","title":"Press Release: Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2530840242","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530840242?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:19","pubTimestamp":1745849940,"startTime":"0","endTime":"0","summary":"Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million. Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases. Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026. The combined company will operate as \"Jade Biosciences, Inc.\" and will trade on Nasdaq under the ticker symbol \"JBIO\". SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025  -- Jade Biosciences, Inc. , a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. . The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol \"JBIO.\". Follow","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","AVTE","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2529081358","title":"BRIEF-Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2529081358","media":"Reuters","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529081358?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:02","pubTimestamp":1745236937,"startTime":"0","endTime":"0","summary":"BRIEF-Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related ProposalsApril 21 (Reuters) - Aerovate Therapeutics Inc AVTE.O:AEROVATE THERAPEUTICS STOCKHOLDERS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8QNVVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","AVTE","BK4539","BK4139"],"gpt_icon":0},{"id":"2529682808","title":"Aerovate Therapeutics Inc - Stockholders Approve Merger With Jade Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682808","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682808?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8QNVVW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["JBIO","AVTE","BK4139","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/JBIO\",params:#limit:5,,,undefined,":[{"date":"2025-04-29","symbol":"JBIO","amount":2.4,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745933400000,"name":"Jade Biosciences","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-28","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-04-28"},{"market":"US","date":"2025-04-29","symbol":"JBIO","defaultRemindTime":1745933400000,"type":"split","dateTimestamp":1745899200000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2025-04-25","symbol":"JBIO","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745553600000,"reportTimeType":"post","actualEps":-0.09},{"market":"US","date":"2025-03-27","symbol":"JBIO","fiscalQuarterEnding":"2024/12","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2024-11-12","symbol":"JBIO","fiscalQuarterEnding":"2024/09","expectedEps":-0.59,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.56}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"JBIO\",market:\"US\",,,undefined,":[{"executeDate":"2025-04-29","recordDate":"2025-04-25","paymentDate":"2025-04-28","value":2.4,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"JBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.2,"hold":0.4,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1746849600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/JBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"JBIO","date":"2025-06-06","current":-2.363881,"percent":1,"low":-2.892256,"twenty":-2.548988,"median":-2.487393,"eighty":-2.464507,"high":-2.363881,"avg":-2.542843,"sd":0.152585,"marketCap":222105530},"quantilePoints":[{"date":"2025-05-16","current":-2.4743,"twenty":-2.881556,"median":-2.868851,"eighty":-2.514424,"marketCap":232480279},{"date":"2025-05-23","current":-2.511409,"twenty":-2.870857,"median":-2.517932,"eighty":-2.47965,"marketCap":235966978},{"date":"2025-05-30","current":-2.432499,"twenty":-2.695315,"median":-2.507901,"eighty":-2.466944,"marketCap":228552715},{"date":"2025-06-06","current":-2.363881,"twenty":-2.548988,"median":-2.487393,"eighty":-2.464507,"marketCap":222105530}],"updateTime":1749506462349}}}